A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review
2021
EJNMMI Research
Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. While most of the existing literature has been focussed on the application of FAP-specific PET in various kinds of cancers, some researchers have, both intentionally or unintentionally, used FAP-specific PET in patients with non-cancerous diseases. The purpose of this systematic review is therefore to summarize the available evidence of
doi:10.1186/s13550-021-00761-2
pmid:33606104
fatcat:v2evfuz4o5hlxgyrdzjnp3mmue